Serina Therapeutics, Inc.

SER ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017
Operating Activities
Net Income $-6.6M
Depreciation & Amortization
Depreciation $165.0K
Amortization $517.0K
Stock-Based Compensation $114.0K
Net Cash from Operating Activities $-6.3M
Investing Activities
Capital Expenditures $1.0K
Business Acquisitions
Net Cash from Investing Activities $5.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $13.3M
Net Change in Cash $7.1M
Free Cash Flow $-6.3M
← Newer Page 2 of 2 Older →